Evaxion Secures Over $30 Million in New Capital for 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy EVAX?
The company said, "Our financial position and equity were significantly enhanced through an influx of new capital totaling more than $30 million in 2025, including the $7.5 million option exercise fee from MSD. As a result, we significantly extended our cash runway and now hold cash on hand to fund our operations into the second half of 2027. Our equity was further bolstered by the debt conversion agreement with the EIB, which also has a rolling positive cash effect in the form of lower interest payments. Further to the extended cash runway, we have also improved our funding options going forward, even if we have no imminent need for new capital. Following the positive development in our market capitalization as a result of MSD's option exercise, we were able to amend our Form F-3 shelf registration and ATM facility. This potentially allows for flexible and cost-effective funding on optimal terms for Evaxion and our shareholders until March 2028. If and when funding needs should arise, we will be able to issue up to $45.5 million worth of Evaxion shares if and when market conditions allow during the coming three years."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EVAX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EVAX
Wall Street analysts forecast EVAX stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.580
Low
10.00
Averages
12.33
High
16.00
Current: 3.580
Low
10.00
Averages
12.33
High
16.00
About EVAX
Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Evaxion A/S Reports Strong Q4 2025 Earnings and Strategic Developments
- Strategic Collaboration Progress: Evaxion A/S's licensing agreement with Merck for the EVX-B3 vaccine candidate marks a significant milestone as the first infectious disease vaccine identified through an AI discovery platform, showcasing the technology's market validation and future potential.
- Improved Financial Position: In 2025, Evaxion achieved a cash inflow of $32 million, with a net loss of $7.7 million, reflecting an improvement from the previous year, and ended with a cash position of $23 million, providing a solid foundation for future R&D and market expansion.
- R&D Pipeline Breakthroughs: The company made significant advancements in its R&D pipeline, with strong Phase II clinical data for EVX-01 in melanoma and the development of the new EVX-04 leukemia vaccine candidate, indicating promising market opportunities ahead.
- Future Outlook: Management anticipates submitting a regulatory application for EVX-04 in 2026, along with updates on biomarker and immunogenicity data for EVX-01, demonstrating ongoing investment in key assets and a keen awareness of market demands.
See More
Evaxion Biotech Reports FY EPS Beat Expectations
- Earnings Highlights: Evaxion Biotech reported a FY GAAP EPS of -$0.02, beating market expectations by $0.01, indicating a slight improvement in financial performance that may boost investor confidence.
- Market Reaction: Although the EPS remains negative, the better-than-expected results could attract more investor interest, potentially enhancing the stock's short-term performance and reflecting market recognition of its future potential.
- Historical Data Comparison: According to Seeking Alpha's Quant Rating, Evaxion Biotech's historical financial data suggests that despite challenges, the company's efforts in revenue and cost control are gradually showing results, which may lay the groundwork for future growth.
- Future Outlook: With ongoing operational optimization and R&D investments, investors maintain an optimistic view of Evaxion Biotech's long-term prospects, particularly regarding its innovation potential in the biotechnology sector.
See More
Evaxion A/S Provides 2025 Business and Financial Update
- Vaccine Licensing Achievement: Evaxion secured a historic licensing agreement with Merck for its infectious disease vaccine candidate EVX-B3, receiving a $7.5 million option exercise fee and potential future milestone payments of up to $592 million, significantly strengthening the company's financial foundation.
- Personalized Cancer Vaccine Progress: EVX-01 demonstrated a 75% objective response rate at the 2025 ESMO conference, with 4 out of 12 patients achieving complete response and 92% maintaining response at two years follow-up, validating the clinical potential of the AI-Immunology™ platform and driving future R&D advancements.
- Pipeline Expansion: Evaxion added EVX-04 and EVX-B4 vaccine candidates targeting acute myeloid leukemia and Group A Streptococcus, respectively, enriching its R&D pipeline with clinical trials expected in the second half of 2026, enhancing the company's competitiveness in cancer and infectious disease sectors.
- Financial Position Improvement: Evaxion's cash and cash equivalents reached $23.2 million in 2025, a significant increase from 2024, driven by over $30 million in capital influx and a debt-to-equity conversion agreement, ensuring sufficient operational funding into the second half of 2027 and enhancing future financing flexibility.
See More
Evaxion to Report 2025 Financial Results on March 5
- Financial Report Release: Evaxion A/S will release its 2025 financial results on March 5, 2026, before the Nasdaq opens, aiming to provide investors with the latest financial status and business updates.
- Management Conference Call: On the same day at 14:30 CET/08:30 EST, Evaxion's executive team will host a conference call and webcast to present the financial results and answer investor questions, enhancing engagement with stakeholders.
- Platform Advantage: Evaxion's AI-Immunology™ platform leverages artificial intelligence to decode the human immune system, focusing on developing innovative vaccines for cancer and infectious diseases, showcasing its leading position in the biotech sector.
- Clinical Pipeline Development: The company has established a clinical pipeline of personalized and off-the-shelf cancer vaccine candidates, reflecting its commitment to addressing high unmet medical needs and aiming to improve patient quality of life.
See More
Evaxion Looks for New Partner for Gonorrhea Vaccine Following Merck's Withdrawal
Merck's Decision on EVX-B2: Merck & Co. has opted not to pursue Evaxion's gonorrhea vaccine candidate EVX-B2, allowing Evaxion to retain global rights and seek other licensing partners.
Gonorrhea Vaccine Landscape: Despite affecting over 80 million people annually, no gonorrhea vaccine has been approved yet, although preclinical studies show promise for EVX-B2.
Evaxion's Financial Outlook: Evaxion's CEO stated that Merck's decision does not impact their financial projections, which extend to the second half of 2027.
Recent Developments: Evaxion has successfully out-licensed another vaccine candidate, EVX-B3, to Merck, receiving an upfront payment and potential future milestone payments, while the FDA recently approved GSK's oral treatment for gonorrhea.
See More
Evaxion Retains Global Rights to EVX-B2 After MSD Declines Option
- Change in Partnership Opportunity: MSD's decision not to exercise its option for Evaxion's Gonorrhea vaccine candidate EVX-B2 allows Evaxion to seek new licensing partners while retaining global rights to the project, although this decision does not impact its cash runway.
- Vaccine Potential: EVX-B2 has demonstrated protective effects against Gonorrhea in preclinical studies, highlighting the potential of Evaxion's AI-Immunology™ platform to develop vaccines that address significant unmet medical needs, despite the absence of approved vaccines to date.
- Financial Stability: Evaxion's cash flow outlook did not include a potential in-licensing of EVX-B2 by MSD, meaning this decision will not affect its cash runway, which is projected to extend into the second half of 2027, ensuring financial flexibility for future R&D activities.
- R&D Direction: Evaxion is also developing an mRNA version of EVX-B2 in collaboration with Afrigen Biologics, further expanding its vaccine pipeline and demonstrating the company's ongoing innovation capabilities in addressing infectious diseases.
See More
Evaxion A/S Reports Strong Q4 2025 Earnings and Strategic Developments
- Strategic Collaboration Progress: Evaxion A/S's licensing agreement with Merck for the EVX-B3 vaccine candidate marks a significant milestone as the first infectious disease vaccine identified through an AI discovery platform, showcasing the technology's market validation and future potential.
- Improved Financial Position: In 2025, Evaxion achieved a cash inflow of $32 million, with a net loss of $7.7 million, reflecting an improvement from the previous year, and ended with a cash position of $23 million, providing a solid foundation for future R&D and market expansion.
- R&D Pipeline Breakthroughs: The company made significant advancements in its R&D pipeline, with strong Phase II clinical data for EVX-01 in melanoma and the development of the new EVX-04 leukemia vaccine candidate, indicating promising market opportunities ahead.
- Future Outlook: Management anticipates submitting a regulatory application for EVX-04 in 2026, along with updates on biomarker and immunogenicity data for EVX-01, demonstrating ongoing investment in key assets and a keen awareness of market demands.
See More
Evaxion Biotech Reports FY EPS Beat Expectations
- Earnings Highlights: Evaxion Biotech reported a FY GAAP EPS of -$0.02, beating market expectations by $0.01, indicating a slight improvement in financial performance that may boost investor confidence.
- Market Reaction: Although the EPS remains negative, the better-than-expected results could attract more investor interest, potentially enhancing the stock's short-term performance and reflecting market recognition of its future potential.
- Historical Data Comparison: According to Seeking Alpha's Quant Rating, Evaxion Biotech's historical financial data suggests that despite challenges, the company's efforts in revenue and cost control are gradually showing results, which may lay the groundwork for future growth.
- Future Outlook: With ongoing operational optimization and R&D investments, investors maintain an optimistic view of Evaxion Biotech's long-term prospects, particularly regarding its innovation potential in the biotechnology sector.
See More
Evaxion A/S Provides 2025 Business and Financial Update
- Vaccine Licensing Achievement: Evaxion secured a historic licensing agreement with Merck for its infectious disease vaccine candidate EVX-B3, receiving a $7.5 million option exercise fee and potential future milestone payments of up to $592 million, significantly strengthening the company's financial foundation.
- Personalized Cancer Vaccine Progress: EVX-01 demonstrated a 75% objective response rate at the 2025 ESMO conference, with 4 out of 12 patients achieving complete response and 92% maintaining response at two years follow-up, validating the clinical potential of the AI-Immunology™ platform and driving future R&D advancements.
- Pipeline Expansion: Evaxion added EVX-04 and EVX-B4 vaccine candidates targeting acute myeloid leukemia and Group A Streptococcus, respectively, enriching its R&D pipeline with clinical trials expected in the second half of 2026, enhancing the company's competitiveness in cancer and infectious disease sectors.
- Financial Position Improvement: Evaxion's cash and cash equivalents reached $23.2 million in 2025, a significant increase from 2024, driven by over $30 million in capital influx and a debt-to-equity conversion agreement, ensuring sufficient operational funding into the second half of 2027 and enhancing future financing flexibility.
See More
Evaxion to Report 2025 Financial Results on March 5
- Financial Report Release: Evaxion A/S will release its 2025 financial results on March 5, 2026, before the Nasdaq opens, aiming to provide investors with the latest financial status and business updates.
- Management Conference Call: On the same day at 14:30 CET/08:30 EST, Evaxion's executive team will host a conference call and webcast to present the financial results and answer investor questions, enhancing engagement with stakeholders.
- Platform Advantage: Evaxion's AI-Immunology™ platform leverages artificial intelligence to decode the human immune system, focusing on developing innovative vaccines for cancer and infectious diseases, showcasing its leading position in the biotech sector.
- Clinical Pipeline Development: The company has established a clinical pipeline of personalized and off-the-shelf cancer vaccine candidates, reflecting its commitment to addressing high unmet medical needs and aiming to improve patient quality of life.
See More
Evaxion Looks for New Partner for Gonorrhea Vaccine Following Merck's Withdrawal
Merck's Decision on EVX-B2: Merck & Co. has opted not to pursue Evaxion's gonorrhea vaccine candidate EVX-B2, allowing Evaxion to retain global rights and seek other licensing partners.
Gonorrhea Vaccine Landscape: Despite affecting over 80 million people annually, no gonorrhea vaccine has been approved yet, although preclinical studies show promise for EVX-B2.
Evaxion's Financial Outlook: Evaxion's CEO stated that Merck's decision does not impact their financial projections, which extend to the second half of 2027.
Recent Developments: Evaxion has successfully out-licensed another vaccine candidate, EVX-B3, to Merck, receiving an upfront payment and potential future milestone payments, while the FDA recently approved GSK's oral treatment for gonorrhea.
See More
Evaxion Retains Global Rights to EVX-B2 After MSD Declines Option
- Change in Partnership Opportunity: MSD's decision not to exercise its option for Evaxion's Gonorrhea vaccine candidate EVX-B2 allows Evaxion to seek new licensing partners while retaining global rights to the project, although this decision does not impact its cash runway.
- Vaccine Potential: EVX-B2 has demonstrated protective effects against Gonorrhea in preclinical studies, highlighting the potential of Evaxion's AI-Immunology™ platform to develop vaccines that address significant unmet medical needs, despite the absence of approved vaccines to date.
- Financial Stability: Evaxion's cash flow outlook did not include a potential in-licensing of EVX-B2 by MSD, meaning this decision will not affect its cash runway, which is projected to extend into the second half of 2027, ensuring financial flexibility for future R&D activities.
- R&D Direction: Evaxion is also developing an mRNA version of EVX-B2 in collaboration with Afrigen Biologics, further expanding its vaccine pipeline and demonstrating the company's ongoing innovation capabilities in addressing infectious diseases.
See More
